Full-Time

Associate Director

Pharmacovigilance Operations

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$170k - $195k/yr

+ Bonus + Equity

Senior, Expert

New York, NY, USA

On-site requirement of at least three days per week; unable to consider candidates looking for fully remote roles.

Category
Public Health
Biology & Biotech
Requirements
  • Bachelor’s degree required. A Master’s degree in Science, or other Health Care Professional degree preferred i.e., MSn, RN, PharmD
  • 8+ years of experience in Pharmacovigilance Operations
  • Extensive experience in case processing, regulatory requirements of ICSRs, MedDRA, WHODD, project management
  • Knowledge of ICH E2B(R2) and (R3) specifications and entry guidance
  • Knowledge of global pharmacovigilance reporting rules and timelines, including but not limited to Health Canada, FDA and EMA
  • Ability to interpret health and medical records such as adverse event reporting forms, a discharge summary, etc.
  • Ability to work on site Monday, Tuesday & Thursday. We are unable to consider candidates who are looking for fully remote roles
Responsibilities
  • Oversee the vendor case processing activities to ensure the quality of safety cases
  • Perform both real-time and retrospective quality control of safety case data entry to ensure quality and compliance with the data entry conventions and MedDRA/WHO DD coding conventions
  • Trend the case quality of both investigational and approved products and communicate to the case processing vendor
  • Develop and review Quality Control reports to identify trends in ICSR related criteria, such as invalid cases, spot data entry errors
  • Ensure ICSR reconciliations are performed with the relevant parties in a timely manner
  • Participate in the vendor quality meetings and governance meetings
  • Oversee the vendor case processing activities to ensure compliance with regulatory submissions and internal timelines including monitoring the workflow status of safety cases and or the pending regulatory submissions of ICSRs
  • Analyze and investigate for late forwarding, data entry, submission/distribution of safety reports, as applicable
  • Support the authoring or review of the periodic safety reports to ensure timely submissions
  • Perform and oversee reconciliations with internal/external stakeholders to ensure cases are exchanged as per the relevant agreement
  • Provide input on behalf of PV Operations on individual study-specific documents including but, but not limited to, Safety Operational Management Plan, SAE Reconciliation Plan, Data Validation Plan, and Safety Reporting Form Specifications Document
  • Support the set-up and maintenance of individual study-specific activities, including, but not limited to Market Research Projects, Patient Support Programs, Patient Assistance Program, Clinical Trials, etc. Support and provide guidance on questions concerning PV Operations based on, not only company conventions, but also regulatory guidance from Health Authorities
  • Contribute to the creation or updating of Standard Operating Procedures, Working Instructions, and training materials concerning safety case processing and operations
  • Support Axsome initiatives and projects representing PV Operations
Desired Qualifications
  • Some experience in signal detection
  • Experience with clinical and/or post-marketing case processing, including medical terminologies, MedDRA and WHO DD coding and narrative writing
  • Experience with safety database; ARISg is a plus but not mandatory
  • Experience with EDC for clinical trial data collection is a plus but not mandatory
  • Excellent in detailed-oriented tasks
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, Alzheimer's agitation, migraine, narcolepsy, fibromyalgia, and smoking cessation. Their main product, AXS-05, is an oral medication that acts as an NMDA receptor antagonist to help regulate mood. It has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Axsome's AXS-07 is anticipated to launch for migraines in 2025.
  • Investments from major firms indicate strong market confidence in Axsome.
  • EMA initiatives may expedite Axsome's entry into the European market.

What critics are saying

  • Increased competition in CNS disorder treatments may impact Axsome's market share.
  • Potential delays in clinical trials could postpone new product launches.
  • Dependence on AXS-05 and AXS-07 could affect financial performance if setbacks occur.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05 has FDA Breakthrough Therapy Designation for major depressive disorder.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Clival
Apr 8th, 2025
Axsome to Present Positive Phase 3 AXS-05 & AXS-12 Results at AAN 2025

Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting, being held April 5-9 in San Diego, California.

Insider Monkey
Feb 23rd, 2025
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).